Zuga Matt

CFO & Chief Business Officer

Zuga Matt has filed 4 SEC Form 4 filings (8 transaction rows) across 1 company, with disclosures dating back to 2026. 4 of those filings fall inside the rolling window. Most recent filing: Jan 23, 2026.

On the most recent filing, Zuga Matt is listed as CFO & Chief Business Officer at Acumen Pharmaceuticals, Inc. Inside the rolling window, Zuga Matt reported no open-market purchases and 6 open-market sales totaling $50K in ABOS. The largest disclosed transaction in the window is a sale of 6,888 ABOS shares on Jan 8, 2026, worth $13K.

Companies traded

Other insiders at ABOS

Insider Buying

$0

reported purchases (SEC code P)

Insider Selling

$50K

reported sales (SEC code S)

Companies

1

in the rolling window

Source
ABOSSale$4KJan 23SEC ↗
ABOSSale$3KJan 23SEC ↗
ABOSSale$13KJan 12SEC ↗
ABOSSale$8KJan 7SEC ↗
ABOSSale$10KJan 7SEC ↗
ABOSSale$12KJan 7SEC ↗
Showing 1–6 of 6
1 / 1

Frequently asked questions

How many SEC Form 4 filings has Zuga Matt made?

Zuga Matt has filed 4 SEC Form 4 filings (8 transaction rows) across 1 company since 2026.

Which companies does Zuga Matt trade?

Zuga Matt has filed SEC Form 4 disclosures for 1 company, including ABOS.

When was Zuga Matt's most recent SEC Form 4 filing?

Zuga Matt's most recent SEC Form 4 filing on Tracefour is dated Jan 23, 2026.

What is Zuga Matt's job title?

On the most recent SEC Form 4 filings tracked by Tracefour, Zuga Matt is listed as CFO & Chief Business Officer.

What is Zuga Matt's total buy and sell value in the current window?

Inside the rolling retention window, Zuga Matt bought $0 and sold $50K based on SEC Form 4 filings.

What was Zuga Matt's largest disclosed transaction?

The largest disclosed transaction in the current window is a sale of 6,888 ABOS shares on 2026-01-08, worth $13K, per SEC Form 4 filings.